BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34839410)

  • 1. Subtyping non-small cell lung cancer by histology-guided spatial metabolomics.
    Neumann JM; Freitag H; Hartmann JS; Niehaus K; Galanis M; Griesshammer M; Kellner U; Bednarz H
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):351-360. PubMed ID: 34839410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens.
    Kriegsmann M; Casadonte R; Kriegsmann J; Dienemann H; Schirmacher P; Hendrik Kobarg J; Schwamborn K; Stenzinger A; Warth A; Weichert W
    Mol Cell Proteomics; 2016 Oct; 15(10):3081-3089. PubMed ID: 27473201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.
    Tan F; Jiang Y; Sun N; Chen Z; Lv Y; Shao K; Li N; Qiu B; Gao Y; Li B; Tan X; Zhou F; Wang Z; Ding D; Wang J; Sun J; Hang J; Shi S; Feng X; He F; He J
    Mol Cell Proteomics; 2012 Feb; 11(2):M111.008821. PubMed ID: 22064513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinguishing Non-Small Cell Lung Cancer Subtypes in Fine Needle Aspiration Biopsies by Desorption Electrospray Ionization Mass Spectrometry Imaging.
    Bensussan AV; Lin J; Guo C; Katz R; Krishnamurthy S; Cressman E; Eberlin LS
    Clin Chem; 2020 Nov; 66(11):1424-1433. PubMed ID: 33141910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens.
    Sigel CS; Moreira AL; Travis WD; Zakowski MF; Thornton RH; Riely GJ; Rekhtman N
    J Thorac Oncol; 2011 Nov; 6(11):1849-56. PubMed ID: 21841504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Napsin A/p40 antibody cocktail for subtyping non-small cell lung carcinoma on cytology and small biopsy specimens.
    Nishino M; Hoang MP; Della Pelle P; Morales-Oyarvide V; Huynh TG; Mark EJ; Mino-Kenudson M
    Cancer Cytopathol; 2016 Jul; 124(7):472-84. PubMed ID: 27412420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid MALDI profile classifies non-small cell lung cancers according to the histologic type.
    Lee GK; Lee HS; Park YS; Lee JH; Lee SC; Lee JH; Lee SJ; Shanta SR; Park HM; Kim HR; Kim IH; Kim YH; Zo JI; Kim KP; Kim HK
    Lung Cancer; 2012 May; 76(2):197-203. PubMed ID: 22099218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Non-small cell lung cancer. New biomarkers for diagnostics and therapy].
    Kayser G
    Pathologe; 2015 Nov; 36 Suppl 2():189-93. PubMed ID: 26391246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.
    Loo PS; Thomas SC; Nicolson MC; Fyfe MN; Kerr KM
    J Thorac Oncol; 2010 Apr; 5(4):442-7. PubMed ID: 20195168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.
    Rekhtman N; Brandt SM; Sigel CS; Friedlander MA; Riely GJ; Travis WD; Zakowski MF; Moreira AL
    J Thorac Oncol; 2011 Mar; 6(3):451-8. PubMed ID: 21266922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robust subtyping of non-small cell lung cancer whole sections through MALDI mass spectrometry imaging.
    Janßen C; Boskamp T; Hauberg-Lotte L; Behrmann J; Deininger SO; Kriegsmann M; Kriegsmann K; Steinbuß G; Winter H; Muley T; Casadonte R; Kriegsmann J; Maaß P
    Proteomics Clin Appl; 2022 Jul; 16(4):e2100068. PubMed ID: 35238465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection and verification of coexisting diagnostic markers in plasma and serum of patients with non-small-cell lung cancer.
    Yu M; Sun R; Zhao Y; Shao F; Zhu W; Aa J
    Future Oncol; 2021 Nov; 17(32):4355-4369. PubMed ID: 34674559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic utility of fine needle aspiration cytology and core biopsy histopathology with or without immunohistochemical staining in the subtyping of the non-small cell lung carcinomas: Experience from an academic centre in Turkey.
    Bayrak BY; Paksoy N; Vural Ç
    Cytopathology; 2021 May; 32(3):331-337. PubMed ID: 33145811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of immunohistochemical staining in diagnosing pulmonary squamous cell carcinoma.
    Yan Y; Zhang YX; Fang WF; Kang SY; Zhan JH; Chen N; Hong SD; Liang WH; Tang YN; He DC; Wu X; Zhang L
    Asian Pac J Cancer Prev; 2015; 16(2):551-7. PubMed ID: 25684486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new technological approach in diagnostic pathology: mass spectrometry imaging-based metabolomics for biomarker detection in urachal cancer.
    Neumann JM; Niehaus K; Neumann N; Knobloch HC; Bremmer F; Krafft U; Kellner U; Nyirády P; Szarvas T; Bednarz H; Reis H
    Lab Invest; 2021 Sep; 101(9):1281-1288. PubMed ID: 34021261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adequacy of endobronchial ultrasound transbronchial needle aspiration samples in the subtyping of non-small cell lung cancer.
    Esterbrook G; Anathhanam S; Plant PK
    Lung Cancer; 2013 Apr; 80(1):30-4. PubMed ID: 23312886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer.
    Hong YJ; Hur J; Lee HJ; Nam JE; Kim YJ; Kim HS; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Choi BW; Choe KO
    J Thorac Oncol; 2011 Aug; 6(8):1330-5. PubMed ID: 21847061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Small Cell Lung Cancer Detection and Subtyping by UPLC-HRMS-Based Tissue Metabolomics.
    Zang X; Zhang J; Jiao P; Xue X; Lv Z
    J Proteome Res; 2022 Aug; 21(8):2011-2022. PubMed ID: 35856400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chaperonin (HSP60) and annexin-2 are candidate biomarkers for non-small cell lung carcinoma.
    Ağababaoğlu İ; Önen A; Demir AB; Aktaş S; Altun Z; Ersöz H; Şanl A; Özdemir N; Akkoçlu A
    Medicine (Baltimore); 2017 Feb; 96(6):e5903. PubMed ID: 28178129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in cancer cell metabolism revealed by direct sample analysis with MALDI mass spectrometry.
    Pirman DA; Efuet E; Ding XP; Pan Y; Tan L; Fischer SM; DuBois RN; Yang P
    PLoS One; 2013; 8(4):e61379. PubMed ID: 23658609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.